Skip to main content
. Author manuscript; available in PMC: 2023 Oct 27.
Published in final edited form as: Cell. 2022 Oct 14;185(22):4170–4189.e20. doi: 10.1016/j.cell.2022.09.008

Figure 5. Substance P is required for tissue protection mediated by TRPV1+ nociceptors.

Figure 5.

(A, B) Colon substance P and CGRP levels in DSS-treated TRPV1hM4Di or their littermate control mice. (C, D) Colon substance P and CGRP levels in DSS-treated TRPV1wt/wt mice infected with AAV9 viruses. (E, F) Colon substance P and CGRP levels in DSS-treated DMSO- or RTX-treated mice. (G to J) Disease and recovery of DSS-treated DMSO- or RTX-treated mice administered with substance P were assessed from day 0 to day 10 by daily weight loss (G), clinical disease score (H), colon length (I) and H&E staining of the distal colon (J) at day 10. (K to N) Disease and recovery of DSS-treated TRPV1hM4Di or their littermate control administered with substance P were assessed by daily weight loss (K), clinical disease score (L), colon length (M) and H&E staining of the distal colon (N) at day 10. Scale bars = 50 μm in (J) and (N). Data are representative of two independent experiments with n=4–5 per group. Data are shown as mean ± SEM. ns, not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.